NIB and Citadele fund Baltics’ first gene therapy manufacturing facility

NIB, Citadele bank and the Lithuanian biopharmaceutical company UAB Celltechna signed a ten-year financing agreement of EUR 37 million for a gene therapy product facility in Vilnius. NIB will provide a EUR 22.5 million loan, and Citadele will extend a EUR 14.5 million loan for the project.

The new Gene Therapy Centre will be the first and so far the only one of its kind in the Baltic countries. It will provide facilities for both research and manufacturing processes, supporting the development of genetic disease treatments.

Spanning approximately 8,000 square metres, the state-of-the-art facility plans to create over 100 new high-value jobs. This will further strengthen Lithuania’s Life Science sector, which has been recently growing amongst the fastest across the European Union.

“With our financing, we support the strategic development of Lithuania’s priority sector”, says Jeanette Vitasp, Vice-President and Head of Lending at NIB. “The project will not only increase the country’s competitiveness in a rapidly advancing field but will also enable significant growth potential for the whole region.”

“We appreciate the opportunity to contribute to Lithuania’s leadership in biotechnology and life sciences. Such strategic projects help to build an economy that is more resilient to future challenges and support a steadfast development of the country”, says Vaidas Žagūnis, Member of the Management Board, Chief Corporate Commercial Officer at Citadele.

Expanding product offerings from biopharmaceuticals to gene therapy treatments marks the initial phase of an ambitious long-term vision to centralise expertise in life sciences. The company plans to build additional biomanufacturing and research facilities in the area to form a large biotechnology hub called BIO CITY.

“We sincerely value the trust and financial loans extended by the NIB and Citadele towards developing the first gene therapy centre in the Baltics, which is one of the key components of the BIO CITY project of Northway Healthcare Group. The completion of this centre within the current year signifies a monumental stride in our plans to establish the largest biotechnology city in Europe, located in Vilnius”, says prof. Vladas Algirdas Bumelis, CEO of Celltechna.

Currently, the Life Science sector generates approximately 2.5% of Lithuania’s GDP. In 2023, the Lithuanian Government revised its long-term strategy with an ambition to increase this to 5% by 2030.

The borrower, Celltechna UAB, is a small biopharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides drug development and manufacturing services to pharmaceutical companies in Europe and the US. The guarantor, Biotechpharma UAB, doing business as Northway Biotech, is a related company with a focus on providing services to pharmaceutical research companies that work on discovering new drugs.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s. Read more at www.nib.int

Citadele bank aims to modernise the capital markets and increase access to financing for private and business clients in the Baltics. In 2023, Citadele provided EUR 897 million in new loans. At the end of the year, its total lending portfolio stood at EUR 2.9 billion, the amount of deposits – EUR 3.8 billion.

For further information, please contact
NIB:
Seppo Halttunen, Senior Banker, at +358 10 618 0411, Seppo.Halttunen@nib.int
Vytautas Brazaitis, Communications, at +358 10 618 0235, Vytautas.Brazaitis@nib.int

Citadele:
Birutė Rutkauskaitė, Head of Corporate Communications for Lithuania, at +370 615 22654, birute.rutkauskaite@citadele.lt